Kymera Therapeutics Inc (KYMR) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Kymera Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Kymera Therapeutics Inc's ROI in the second quarter of 2026?
Kymera Therapeutics Inc recorded a cumulative net loss of $-300 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -20.11%.
Within the Healthcare sector 307 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 3376, from total ROI ranking in the first quarter of 2026 at 3995.
Quarterly Edition: Autumn 2023 Kymera Therapeutics Unveils Preclinical Insights on KT-621: A Pioneer in Oral STAT6 Degradation By CSIMarket.com: Dr. Henry M. Archibald In the grand tradition of pharmaceutical innovation, Kymera Therapeutics has presented, at the distinguished EADV Congress, preclinical findings on a novel and promising agent, KT-621. This molecule, imbued with the sophistication of modern medicinal chemistry, has divulged a robust pharmacological profile, positioning it as a formidable antagonist to the nefarious Signal Transducer and Activator of Transcription 6 (STAT6).KT-621 emerges as a potent and selective oral degrader of STAT6, an agent of great pertinence in the therapeutic expanse of Type 2 helper T cell (TH2) mediated allergic and atopic disorders. The unparalleled sophistication of KT-621 resides in its ability to emulate the therapeutic propensity of dupilumab a monoclonal antibody revered for its efficacy yet, it does so with the elegance and convenience of an oral administration regimen, a feature duly coveted in pharmaceutical design.
In a groundbreaking move, Kymera Therapeutics, a leading biotechnology company, has laid out its key objectives and strategic vision for the year 2024. Combining innovative science with a patient-centric approach, Kymera aims to advance its portfolio of Immunology and Oncology programs. The company s recent announcement of the expected completion of enrollment and topline data from the Phase 2 HS and AD studies of its IRAK4 oral degrader, KT-474 (SAR444656), reaffirms its commitment to transforming the landscape of healthcare. Overview of Kymera Therapeutics: Kymera Therapeutics is at the forefront of developing novel therapeutics that harness the body s innate cellular machinery to target and degrade disease-causing proteins. By focusing on the ubiquitin-proteasome system, which regulates protein degradation, Kymera aims to disrupt disease signaling pathways and offer transformative treatments for patients suffering from various diseases, particularly in the fields of immunology and oncology.
Kymera Therapeutics Announces Successful Pricing of $275 Million Public Offering, Setting the Stage for Continued Progress in Targeted Protein Degradation WATERTOWN, Mass., January 5, 2024 - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a pioneering clinical-stage biopharmaceutical company leveraging targeted protein degradation (TPD) to develop a new class of small molecule medicines, is pleased to announce the successful pricing of its underwritten public offering. The company is offering $275 million worth of shares of its common stock, alongside pre-funded warrants to purchase additional shares of common stock. This milestone not only signifies confidence in Kymera s innovative approach but also provides them with substantial financial resources to further advance their groundbreaking therapies. With this offering, Kymera is selling a total of 2,250,495 shares of common stock and has placed pre-funded warrants to acquire 8,640,594 shares of common stock with specific investors. The shares of common stock are being sold at a public offering price of $25.25 per share, while the pre-funded warrants are being offered at a price of $25.2499 per warrant. The total gross proceeds from this offering are expected to reach approximately $275 million, barring any exercise of the pre-funded warrants or the underwriters option to purchase additional shares. After deducting underwriting discounts, commissions, and estimated offering expenses payable by Kymera, these funds will further empower Kymera s mission of advancing targeted protein degradation therapies.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
